Navigation Links
Rutgers research partner Stemcyte, Inc., expands to New Jersey
Date:5/1/2008

NEW BRUNSWICK, N.J. Officials from Rutgers University and state government today welcomed StemCyte, Inc., to the Garden State. One of the factors in the companys decision to move into New Jersey was a desire to be closer to Rutgers and the groundbreaking research taking place at the university.

StemCytes new office in Ewing Township will house members of its executive management and therapeutics team, establishing a base of operations for the companys northeast United States therapeutics program. StemCyte is a global umbilical cord blood (UCB) stem cell and therapeutic products company.

Rutgers and StemCyte have been collaborating on a spinal cord injury therapy in development by Dr. Wise Young, the Richard H. Shindell Professor of Neuroscience. Youngs therapy, which uses StemCytes proprietary human UCB stem cells in conjunction with lithium, is undergoing clinical trials in China in a network of medical facilities brought together by Young.

I am proud of New Jersey's and Rutger's commitment to stem cell therapeutics, Young said. StemCyte is the only company today that is actually curing hundreds of people with stem cells. Over the past six years, StemCyte has treated patients with 35 types of diseases in 32 countries with a UCB stem cell product.

The synergy emanating from this partnership of academia and industry is already global in its scope, said Richard L. McCormick, president of Rutgers, The State University of New Jersey. Dr. Youngs work with people in China offers new hope to spinal cord injury patients and their families here in New Jersey and worldwide. We are pleased to welcome StemCyte as new neighbors in a statewide community that is focused on medical progress.

To further encourage this industrial-academic research and development partnership, the New Jersey Economic Development Authority is supporting StemCytes move with a 10-year Business Employment Incentive Program (BEIP) grant that will facilitate the 12 new executive-level jobs the company is bringing to the state.

New Jersey continues to provide an innovative and collaborative environment for landmark stem cell research opportunities, Gov. Jon S. Corzine said. The addition of StemCyte to our portfolio of companies represents an important economic investment that brings with it the promise of discovery and cures for some of our most devastating diseases and injuries. I am proud to welcome StemCyte to the Garden State.

Proximity to Rutgers and the BEIP grant were both important considerations in StemCytes decision to move to New Jersey.

The research being done by Dr. Young at Rutgers is top notch, said Kenneth J. Giacin, chair and chief executive officer of StemCyte. In addition, Gov. Corzines plan for developing New Jersey as an active hub for stem cell research and therapeutics development was an important reason for our decision to move our East Coast operations to the state. Were pleased to become an integral part of New Jerseys life sciences community with our focus on therapies derived from umbilical cord blood.

StemCyte, which also has announced the development of a facility in India in collaboration with Cadila Pharmaceuticals and Apollo Hospitals, has operations in California and Taiwan. These facilities collect, process and store UCB stem cells to be used as therapeutic treatments. Unlike embryonic stem cells, which have been the subject of much public controversy, UCB stem cells are harvested from umbilical cords that would otherwise be discarded at the time of childbirth.


'/>"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related medicine news :

1. The Zonta Club of Essex County honors Rutgers College of Nursings Rachel Jones
2. Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing
3. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
4. NJSNA honors Rutgers College of Nursings Linda Flynn for excellence in research
5. Rutgers center sparks liquid bandage, a new frontline wound treatment
6. Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award
7. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
8. N.J. nurses are overworked according to Rutgers College of Nursing professor
9. Rutgers biomaterial debuts in clinical trials of new stent
10. Rutgers College of Nursing faculty member Rachel Jones wins New York Times Nurse Award
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: